Travere Therapeutics (NASDAQ:TVTX) Given New $67.00 Price Target at Leerink Partners

Posted by Brian Himes on Nov 5th, 2026

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target lowered by research analysts at Leerink Partners from $78.00 to $67.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners‘s price target would suggest a potential upside of 37.10% from the stock’s current price.

TVTX has been the subject of a number of other research reports. Wedbush restated an “outperform” rating and set a $76.00 price target on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore set a $78.00 price objective on shares of Travere Therapeutics in a research note on Monday, August 10th. Piper Sandler reiterated an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. Finally, Citigroup boosted their target price on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $68.45.

View Our Latest Stock Report on Travere Therapeutics

Travere Therapeutics Stock Down 6.8%

Travere Therapeutics stock traded down $3.55 during midday trading on Thursday, reaching $48.87. The stock had a trading volume of 2,180,102 shares, compared to its average volume of 2,047,421. Travere Therapeutics has a 12 month low of $22.59 and a 12 month high of $68.73. The company has a market capitalization of $4.69 billion, a P/E ratio of -37.88 and a beta of 1.11. The company has a fifty day moving average price of $58.12 and a two-hundred day moving average price of $46.79. The company has a current ratio of 3.00, a quick ratio of 3.99 and a debt-to-equity ratio of 26.72.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The firm had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same period last year, the company posted $0.28 earnings per share. The firm’s quarterly revenue was up 36.2% compared to the same quarter last year. As a group, equities analysts expect that Travere Therapeutics will post -0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jula Inrig sold 44,674 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $2,784,977.16. Following the completion of the sale, the executive vice president owned 100,491 shares in the company, valued at $6,264,608.94. This represents a 30.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Rote sold 112,850 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $63.33, for a total transaction of $7,146,790.50. Following the completion of the sale, the insider owned 98,197 shares of the company’s stock, valued at approximately $6,218,816.01. This represents a 53.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,294,029 shares of company stock worth $79,454,261 in the last three months. 4.44% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new position in Travere Therapeutics in the second quarter worth $643,299,000. Bank of America Corp DE bought a new position in Travere Therapeutics in the second quarter valued at $259,527,000. Wellington Management Group LLP raised its position in Travere Therapeutics by 50.0% during the second quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after purchasing an additional 510,808 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Travere Therapeutics by 168.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock valued at $67,442,000 after purchasing an additional 718,109 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in Travere Therapeutics during the second quarter valued at about $26,723,000.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

Positive Sentiment: HC Wainwright raised its earnings estimates across 2027–2030, including lifting its 2030 EPS forecast to $6.84 from $5.73. It maintained a Buy rating and a $67 price target, signaling stronger longer-term profit expectations. Travere Therapeutics analyst information
Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and kept a Buy rating. Canaccord Genuity recommendations
Neutral Sentiment: Guggenheim lowered its target to $78 from $89 but maintained a Buy rating, reflecting a more cautious valuation while remaining positive on the shares. Guggenheim recommendations
Negative Sentiment: The main near-term headwind is Travere’s quarterly adjusted loss of $0.55 per share, substantially worse than the $0.06 loss analysts expected. Revenue beat estimates at $224.56 million and grew 36.2% year over year, but the earnings shortfall appears to have weighed on the stock. Travere shares gap down after earnings miss

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.